tradingkey.logo
tradingkey.logo

QuidelOrtho Corp

QDEL
33.645USD
+0.135+0.40%
終値 01/09, 16:00ET15分遅れの株価
2.28B時価総額
損失額直近12ヶ月PER

QuidelOrtho Corp

33.645
+0.135+0.40%

詳細情報 QuidelOrtho Corp 企業名

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.

QuidelOrtho Corpの企業情報

企業コードQDEL
会社名QuidelOrtho Corp
上場日Feb 01, 1991
最高経営責任者「CEO」Blaser (Brian J)
従業員数6600
証券種類Ordinary Share
決算期末Feb 01
本社所在地9975 Summers Ridge Road
都市SAN DIEGO
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号92121
電話番号18585521100
ウェブサイトhttps://www.quidelortho.com/
企業コードQDEL
上場日Feb 01, 1991
最高経営責任者「CEO」Blaser (Brian J)

QuidelOrtho Corpの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9215.00%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+4929.00%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+14410.00%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
32.03K
+2632.00%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+5650.00%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
15.02K
+750.00%
Mr. Brian J. Blaser
Mr. Brian J. Blaser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.45K
+11451.00%
Mr. John R. Chiminski
Mr. John R. Chiminski
Independent Director
Independent Director
2.52K
+2523.00%
Dr. Mary Lake Polan, M.D., Ph.D.
Dr. Mary Lake Polan, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9215.00%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+4929.00%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+14410.00%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
32.03K
+2632.00%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+5650.00%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
15.02K
+750.00%

収益内訳

通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Labs
373.80M
53.41%
Point-of-Care
164.60M
23.52%
Immunohematology
142.00M
20.29%
Donor Screening
14.70M
2.10%
Molecular Diagnostic Solutions
4.80M
0.69%
地域別USD
会社名
収益
比率
North America
381.40M
54.49%
Other
142.10M
20.30%
EMEA
91.80M
13.12%
China
84.60M
12.09%
事業別
地域別
事業別USD
会社名
収益
比率
Labs
373.80M
53.41%
Point-of-Care
164.60M
23.52%
Immunohematology
142.00M
20.29%
Donor Screening
14.70M
2.10%
Molecular Diagnostic Solutions
4.80M
0.69%

株主

更新時刻: Mon, Nov 17
更新時刻: Mon, Nov 17
株主統計
種類
株主統計
株主統計
比率
T. Rowe Price Investment Management, Inc.
16.21%
BlackRock Institutional Trust Company, N.A.
13.72%
The Vanguard Group, Inc.
11.19%
Rubric Capital Management LP
6.83%
Fidelity Management & Research Company LLC
6.54%
他の
45.52%
株主統計
株主統計
比率
T. Rowe Price Investment Management, Inc.
16.21%
BlackRock Institutional Trust Company, N.A.
13.72%
The Vanguard Group, Inc.
11.19%
Rubric Capital Management LP
6.83%
Fidelity Management & Research Company LLC
6.54%
他の
45.52%
種類
株主統計
比率
Investment Advisor
68.41%
Investment Advisor/Hedge Fund
35.84%
Hedge Fund
14.73%
Research Firm
2.25%
Pension Fund
1.07%
Individual Investor
0.95%
Private Equity
0.76%
Bank and Trust
0.61%
Sovereign Wealth Fund
0.52%

機関投資家保有株

更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
652
84.39M
124.22%
-20.78M
2025Q3
656
79.44M
116.95%
-23.17M
2025Q2
684
78.51M
115.63%
-21.42M
2025Q1
726
76.59M
113.26%
-21.60M
2024Q4
747
75.07M
111.30%
-13.02M
2024Q3
744
73.58M
109.44%
-4.02M
2024Q2
767
70.18M
104.79%
-7.57M
2024Q1
799
67.05M
100.24%
-5.28M
2023Q4
828
68.21M
102.09%
-2.95M
2023Q3
842
70.19M
105.17%
-4.01M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
T. Rowe Price Investment Management, Inc.
11.01M
16.21%
-124.03K
-1.11%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
9.32M
13.72%
+39.16K
+0.42%
Sep 30, 2025
The Vanguard Group, Inc.
7.60M
11.19%
-165.71K
-2.13%
Sep 30, 2025
Rubric Capital Management LP
4.64M
6.83%
--
--
Sep 30, 2025
Fidelity Management & Research Company LLC
4.44M
6.54%
+1.89M
+73.81%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
2.86M
4.21%
+350.64K
+13.98%
Sep 30, 2025
Newtyn Management, LLC
2.70M
3.97%
+994.33K
+58.30%
Sep 30, 2025
State Street Investment Management (US)
2.67M
3.93%
-32.20K
-1.19%
Sep 30, 2025
Invesco Advisers, Inc.
2.66M
3.92%
+1.33M
+100.02%
Sep 30, 2025
American Century Investment Management, Inc.
2.12M
3.11%
+199.91K
+10.44%
Sep 30, 2025
詳細を見る

関連ETF

更新時刻: Tue, Dec 2
更新時刻: Tue, Dec 2
銘柄名
比率
State Street SPDR S&P Health Care Equipment ETF
1.75%
Invesco S&P SmallCap Health Care ETF
1.12%
Ballast Small/Mid Cap ETF
0.94%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.56%
JPMorgan Fundamental Data Science Small Core ETF
0.35%
State Street SPDR S&P 600 Small Cap Value ETF
0.26%
Avantis US Small Cap Value ETF
0.26%
iShares S&P Small-Cap 600 Value ETF
0.25%
iShares U.S. Medical Devices ETF
0.22%
State Street SPDR S&P SmallCap 600 ESG ETF
0.19%
詳細を見る
State Street SPDR S&P Health Care Equipment ETF
比率1.75%
Invesco S&P SmallCap Health Care ETF
比率1.12%
Ballast Small/Mid Cap ETF
比率0.94%
First Trust Nasdaq Lux Digi Health Solutions ETF
比率0.56%
JPMorgan Fundamental Data Science Small Core ETF
比率0.35%
State Street SPDR S&P 600 Small Cap Value ETF
比率0.26%
Avantis US Small Cap Value ETF
比率0.26%
iShares S&P Small-Cap 600 Value ETF
比率0.25%
iShares U.S. Medical Devices ETF
比率0.22%
State Street SPDR S&P SmallCap 600 ESG ETF
比率0.19%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし

よくある質問

QuidelOrtho Corpの上位5名の株主は誰ですか?

QuidelOrtho Corpの上位5名の株主は以下のとおりです。
T. Rowe Price Investment Management, Inc.は11.01M株を保有しており、これは全体の16.21%に相当します。
BlackRock Institutional Trust Company, N.A.は9.32M株を保有しており、これは全体の13.72%に相当します。
The Vanguard Group, Inc.は7.60M株を保有しており、これは全体の11.19%に相当します。
Rubric Capital Management LPは4.64M株を保有しており、これは全体の6.83%に相当します。
Fidelity Management & Research Company LLCは4.44M株を保有しており、これは全体の6.54%に相当します。

QuidelOrtho Corpの株主タイプ上位3種は何ですか?

QuidelOrtho Corpの株主タイプ上位3種は、
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.

QuidelOrtho Corp(QDEL)の株式を保有している機関の数はいくつですか?

2025Q4時点で、QuidelOrtho Corpの株式を保有している機関は652社あり、保有株式の総市場価値は約84.39Mで、全体の124.22%を占めています。2025Q3と比較して、機関の持ち株は7.27%増加しています。

QuidelOrtho Corpの最大の収益源は何ですか?

FY2025Q3において、Labs部門がQuidelOrtho Corpにとって最大の収益を生み出しており、その金額は373.80Mで、全収益の53.41%を占めています。
KeyAI